AccessibilityHelpAbout Us
Devonian Health Group logo

Devonian Health Group(OTC) DVHGF

Market Cap$15.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-76%
5 YearN/A
1 Year-50%
1 Month-23%
$5.42
+0.00%
+0.00Today
Devonian Health Group last closing stock price
MetricPriceDate
Last closeUSD 5.422026-08-19
Devonian Health Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-22.57%USD 7.002026-08-05
1 month-22.57%USD 7.002026-06-23
3 month-49.11%USD 10.652026-03-27
Year to date+27.05%USD 4.272025-10-21
1 year-49.81%USD 10.802025-05-06
Since inception-76%USD 24.482022-09-19

Devonian Health Group Financials at a Glance

Market Cap

$15.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$2.64M

Net Income (TTM)

-CA$6.01M

EPS (TTM)

-$1.61

P/E Ratio

-3.36

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$5.42

Volume

50

Open

$5.42

Previous Close

$5.42

Daily Range

$5.42 - $5.42

52-Week Range

$0.07 - $10.65

Estimated Earnings Date

Jun 29, 2026

DVHGF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Devonian Health Group

Devonian Health Group Inc. specializes in developing botanical-based pharmaceutical drugs, focusing on innovative treatments for various health conditions. The company is advancing its lead product candidate, Thykamine, through Phase IIa clinical trials, targeting conditions such as ulcerative colitis and atopic dermatitis.

Products and Services
  • Thykamine for ulcerative colitis and atopic dermatitis
  • Pantoprazole Magnesium for gastric ulcers
  • Cleo-35 targeting hormonal acne in women
Growth Outlook
  • Strategic partnership with CannTx Life Sciences for cannabinoid-based drugs
  • Expanding pipeline with multiple product candidates in development
  • Potential market growth in botanical pharmaceuticals and dermo-cosmetics
Financial Highlights
  • Recent quarterly revenue of CAD 176,581, showing product traction
  • Trailing twelve months gross profit margin at 58.1%, indicating strong product demand
  • Cash and cash equivalents of CAD 719,692, supporting ongoing operations
Devonian Health Group Inc. is positioned in the biotechnology sector, focusing on innovative, plant-based therapies. The company’s lead product, Thykamine, is currently in clinical trials, which could pave the way for significant market opportunities. The strategic partnership with CannTx Life Sciences Inc. enhances its capabilities in developing cannabinoid-based pharmaceuticals, reflecting a commitment to expanding its product offerings. Financially, the company has shown resilience with a gross profit margin of 58.1% over the trailing twelve months, indicating effective cost management and product demand. The recent quarterly revenue of CAD 176,581 suggests a growing interest in its product pipeline. With cash reserves of CAD 719,692, Devonian Health Group Inc. is well-positioned to continue its research and development efforts, potentially leading to future growth and expansion in the biotechnology market.
AI Generated • Aug 27, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

11

CEO

André P. Boulet, PhD

Website

groupedevonian.com

Headquarters

Québec, QC G5V 4T1, CA

DVHGF Financials

Key Financial Metrics (TTM)

Gross Margin

58.11%

Operating Margin

-230.37%

Net Income Margin

-227.68%

Return on Equity

-77.36%

Return on Capital

-15.29%

Return on Assets

-69.69%

Earnings Yield

-29.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.78M

Volume

50

Avg. Volume

6.383

Financials (TTM)

Gross Profit

CA$1.53M

Operating Income

-CA$6.08M

EBITDA

-CA$10.93M

Operating Cash Flow

-CA$11.77M

Capital Expenditure

-CA$6.51K

Free Cash Flow

-CA$11.78M

Cash & ST Invst.

CA$719.69K

Total Debt

CA$140.49K

Devonian Health Group Performance Analysis

Devonian Health Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-07-31CAD 1,747,9361.1%
20242024-01-31CAD 2,622,86750.1%
20242024-07-31CAD 14,205,16750.1%
20252025-07-31CAD 16,914,56719.1%
Devonian Health Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31-87.5%
Q12025-10-3114.0%
Q22026-01-31-53.6%
Q32026-04-30-63.9%
Devonian Health Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-07-31CAD -1.5210.8%
20242024-01-31CAD -0.01-99.5%
20242024-07-31CAD -0.55-99.5%
20252025-07-31CAD -1.75218.3%
Devonian Health Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-3194.0%
Q12025-10-31-418.5%
Q22026-01-31-44.6%
Q32026-04-3012.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$176.58K

-97.6%

Gross Profit

CA$144.96K

-94.6%

Gross Margin

82.09%

N/A

Market Cap

$15.07MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.88M

N/A

Employees

8

N/A

Net Income

-CA$1.94M

+59.6%

EBITDA

-CA$1.88M

-3304.1%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$719.69K

-92.6%

Total Debt

CA$140.49K

+2.4%

Accounts Receivable

CA$520.27K

-90.8%

Inventory

CA$5.78K

-88.0%

Long Term Debt

CA$59.90K

-33.7%

Short Term Debt

CA$161.22K

+243.8%

Return on Assets

-69.69%

N/A

Return on Invested Capital

-86.46%

N/A

Free Cash Flow

-CA$731.87K

-154.3%

Operating Cash Flow

-CA$731.87K

-154.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INTIInhibitor Therapeutics, Inc.
$0.09+0.00%
LVCLFAlgorae Pharmaceuticals Limited
$0.01+0.00%
IMUCEOM Pharmaceuticals Holdings, Inc.
$0.16-10.50%
SPLTFSpotLite360 IOT Solutions, Inc.
$0.08+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$108.80+7.67%
NOKNokia
$10.60+4.54%
DAICCid HoldCo
$5.30+163.68%
NVDANvidia
$219.34+2.54%

Questions About DVHGF

What is the current price of Devonian Health Group?

Devonian Health Group is trading at $5.42 per share.

What is the 52-week range for Devonian Health Group?

Over the past 52 weeks, Devonian Health Group has traded between $0.07 and $10.65.

How much debt does Devonian Health Group have?

As of the most recent reporting period, Devonian Health Group reported total debt of CA$103.26K.

How much cash does Devonian Health Group have on hand?

Devonian Health Group reported CA$528.93K in cash and cash equivalents in its most recent financial results.

What is Devonian Health Group’s dividend yield?

Devonian Health Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services